Loading
A phase 1/2 trial of Toripalimab in advanced solid tumours, run by Advenchen Laboratories, LLC, now recruiting.
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT07392736 by Advenchen Laboratories, LLC, with 228 participants planned, started 2021-10-26 and due to reach its primary completion in 2029-11-07. Interventions recorded: AL8326 tablets and Toripalimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Advenchen Laboratories and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/